Drug intelligence / Profile preview

BIRV

Development stage: Unknown
Lead developer: BioNTech
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

BIRV is a bivalent influenza vaccine developed by BioNTech SE. It is administered via intramuscular injection and is designed to induce an immune response against two specific influenza virus strains. It is currently being evaluated in a Phase 1/2 clinical study.

Targets

HA0 (Influenza B virus hemagglutinin)

Beyond the preview

Go deeper on BIRV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIRV.

Explore the full profile